CytRx Corporation (NASDAQ:CYTR) reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -12.76% in last session and finished the day at $4.17. Traded volume was 11,065,087 million shares in the last session and the average volume of the stock remained 3.51 million shares. The beta of the stock remained 1.51. CytRx Corporation (NASDAQ:CYTR) insider ownership is 11.30%.

Galena Biopharma Inc (NASDAQ:GALE) paid a stock promoter $50,000 to try to goose its share price while insiders dumped $14.6 million of their own shares, a shareholder claims in a derivative complaint. Galena Biopharma Inc (NASDAQ:GALE) dropped -7.08 percent to $3.02 yesterday on volume of 10.18 million shares. The intra-day range of the stock was $2.90 to $3.31. Galena Biopharma Inc (NASDAQ:GALE) has a market capitalization of $317.81 million.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. The company said its fourth quarter revenues totaled $6.5 million, including $2.4 million in BELVIQ product revenue, of which $2.3 million represented 31.5% of Eisai’s net product sales and $0.1 million related to redemptions of the 15-day free trial voucher. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on Mar13, 2014 reported a decrease of -6.44% to the closing price of $6.68. Its fifty two weeks range is $4.05 -$9.25. The total market capitalization recorded $1.46 billion. The overall volume in the last trading session was 7,785,525 million shares. In its share capital, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has 218.64 million outstanding shares.

ACADIA Pharmaceuticals (NASDAQ:ACAD) Director Bros. Advisors Lp Baker purchased 526,316 shares of the stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average price of $28.50 per share, for a total transaction of $15,000,006.00. On Thursday, shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) dropped -6.17% to close the day at $26.78. Company return on investment (ROI) is -24.60% and its monthly performance is recorded as 8.07%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) quarterly revenue growth is 13.47%.